Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.
A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET, with an audio-only webcast option available via the events and presentations section.
Positive
- None.
Negative
- None.
News Market Reaction – HBIO
On the day this news was published, HBIO declined 4.31%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HBIO’s -3.7% move contrasts with mixed peers: BNGO +3.64%, RVP +4.64%, NXGL -1.74%, MHUA -27.18%, POCI -3%, suggesting stock-specific factors.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings call scheduled | Neutral | -0.5% | Set date for Q4 2025 results and earnings call webcast. |
| Feb 10 | Prelim Q4 results | Positive | +13.4% | Preliminary Q4 beat on revenue and margins, EBITDA growth and 2026 focus. |
| Jan 29 | Manufacturing consolidation | Neutral | -6.7% | Announced plant closure and global production shift for long-term savings. |
| Dec 17 | Debt refinancing | Positive | +12.4% | Secured new <b>$40.0M</b> credit facility to refinance debt and extend maturities. |
| Nov 06 | Q3 2025 earnings | Negative | -7.3% | Reported net loss and goodwill impairment despite guidance and backlog strength. |
Positive financing and preliminary results news have recently coincided with notable price gains, while operational restructurings and earnings have seen pressure.
Over the last several months, Harvard Bioscience has focused on refinancing, operational restructuring, and earnings execution. A December 2025 debt refinancing with a $40.0M facility and a February 2026 preliminary Q4 update both saw strong positive price reactions. In contrast, the January 2026 manufacturing consolidation announcement and Q3 2025 earnings drew negative reactions despite cost-saving and backlog details. The current forum participation news fits into a pattern of ongoing investor outreach alongside strategic and financial updates.
Regulatory & Risk Context
An effective S-3 resale registration dated Jan 30, 2026 covers up to 9,500,000 shares for selling securityholders, including warrant and convertible loan shares. The company itself is not selling shares and would only receive up to $1.0 million if the registered warrants are exercised for cash.
Market Pulse Summary
This announcement highlights Harvard Bioscience’s participation in a virtual healthcare forum, including a fireside chat at 2:15pm ET on March 17. It reinforces ongoing investor outreach following recent refinancing, restructuring, and preliminary earnings updates. Investors may focus on how management messages around cost savings, balance sheet changes, and strategic priorities evolve at such events, and track upcoming milestones like the scheduled earnings call and any further regulatory filings or capital structure developments.
AI-generated analysis. Not financial advice.
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET that day.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
FAQ
When will Harvard Bioscience (HBIO) present at KeyBanc’s Virtual Healthcare Forum?
Who from Harvard Bioscience (HBIO) will speak at the March 17, 2026 forum?
How can investors access Harvard Bioscience’s (HBIO) webcast on March 17, 2026?
Will the Harvard Bioscience (HBIO) presentation at the forum include an audio-only option?
What topics will Harvard Bioscience (HBIO) cover during the KeyBanc Virtual Healthcare Forum?
